190 related articles for article (PubMed ID: 27183527)
1. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S64-75. PubMed ID: 27183527
[TBL] [Abstract][Full Text] [Related]
2. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e64-e75. PubMed ID: 27755244
[TBL] [Abstract][Full Text] [Related]
3. Pathophysiology of anthracycline cardiotoxicity.
Mele D; Tocchetti CG; Pagliaro P; Madonna R; Novo G; Pepe A; Zito C; Maurea N; Spallarossa P
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S3-S11. PubMed ID: 27183523
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.
Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
6. Left Ventricular Dysfunction and Chemotherapeutic Agents.
Clasen SC; Wald JW
Curr Cardiol Rep; 2018 Mar; 20(4):20. PubMed ID: 29520629
[TBL] [Abstract][Full Text] [Related]
7. Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection.
Deidda M; Madonna R; Mango R; Pagliaro P; Bassareo PP; Cugusi L; Romano S; Penco M; Romeo F; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S76-83. PubMed ID: 27183528
[TBL] [Abstract][Full Text] [Related]
8. Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy.
Madeddu C; Deidda M; Piras A; Cadeddu C; Demurtas L; Puzzoni M; Piscopo G; Scartozzi M; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S12-8. PubMed ID: 27183520
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-induced cardiotoxicity: detection, prevention, and management.
Truong J; Yan AT; Cramarossa G; Chan KK
Can J Cardiol; 2014 Aug; 30(8):869-78. PubMed ID: 25064580
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy-induced cardiomyopathy.
Higgins AY; O'Halloran TD; Chang JD
Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological foundations of cardio-oncology.
Minotti G; Salvatorelli E; Menna P
J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
[TBL] [Abstract][Full Text] [Related]
13. A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology.
Spallarossa P; Maurea N; Cadeddu C; Madonna R; Mele D; Monte I; Novo G; Pagliaro P; Pepe A; Tocchetti CG; Zito C; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1(Suppl 1):S84-92. PubMed ID: 27183529
[TBL] [Abstract][Full Text] [Related]
14. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.
Raschi E; Vasina V; Ursino MG; Boriani G; Martoni A; De Ponti F
Pharmacol Ther; 2010 Feb; 125(2):196-218. PubMed ID: 19874849
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
Albini A; Pennesi G; Donatelli F; Cammarota R; De Flora S; Noonan DM
J Natl Cancer Inst; 2010 Jan; 102(1):14-25. PubMed ID: 20007921
[TBL] [Abstract][Full Text] [Related]
16. Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss.
Cardinale D; Biasillo G; Cipolla CM
Curr Cardiol Rep; 2016 Jun; 18(6):51. PubMed ID: 27108361
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic prevention of anthracycline-induced cardiomyopathy.
Maradia K; Guglin M
Cardiol Rev; 2009; 17(5):243-52. PubMed ID: 19690476
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S19-26. PubMed ID: 27183521
[TBL] [Abstract][Full Text] [Related]
19. The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity.
Reis-Mendes AF; Sousa E; de Lourdes Bastos M; Costa VM
Curr Drug Metab; 2015; 17(1):75-90. PubMed ID: 26526839
[TBL] [Abstract][Full Text] [Related]
20. The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs.
Hrynchak I; Sousa E; Pinto M; Costa VM
Drug Metab Rev; 2017 May; 49(2):158-196. PubMed ID: 28393622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]